Skip to main content

Table 1 Clinicopathologic features of the DCIS, mIDC, and IDC lesions in the study cohort

From: The role of MRI and clinicopathologic features in predicting the invasive component of biopsy-confirmed ductal carcinoma in situ

  DCIS (n = 112) mIDC (n = 50) IDC (n = 44) P value
Age, years 48.6 ± 10.3 50.3 ± 11.5 52.1 ± 10.8 0.181
Biopsy method     0.028
 SVAB 28 (25.0) 6 (12.0) 4 (9.1)  
 US-CNB 84 (75.0) 44 (88.0) 40 (90.9)  
Surgery type     < 0.001
 Breast conserving 80 (71.4) 29 (58.0) 15 (34.1)  
 Mastectomy 32 (28.6) 21 (42.0) 29 (65.9)  
Nuclear grade     0.001
 1 15 (13.4) 4 (8.0) 1 (2.3)  
 2 88 (78.6) 30 (60.0) 29 (65.9)  
 3 9 (8.0) 16 (32.0) 14 (31.8)  
Necrosis     0.073
 Present 54 (47.4) 33 (66.0) 27 (61.4)  
 Absent 58 (51.8) 17 (34.0) 17 (38.6)  
Pathologic tumor size (cm) 2.0 ± 1.6 3.7 ± 2.3 4.5 ± 2.4 < 0.001
Estrogen receptor     < 0.001
 Positive 103 (92.0) 26 (52.0) 34 (77.3)  
 Negative 9 (8.0) 24 (48.0) 10 (22.7)  
Progesterone receptor     < 0.001
 Positive 95 (84.8) 21 (42.0) 26 (59.1)  
 Negative 17 (15.2) 29 (58.0) 18 (40.9)  
HER2     < 0.001
 Positive 20 (17.9) 30 (60.0) 16 (36.4)  
 Negative 92 (82.1) 20 (40.0) 28 (63.6)  
Ki-67     < 0.001
 High (≥20%) 24 (21.4) 24 (48.0) 24 (54.5)  
 Low (< 20%) 88 (78.6) 26 (52.0) 20 (45.5)  
  1. Data values indicate the number of patients (with percentages in parentheses), or the mean ± standard deviation.
  2. DCIS ductal carcinoma in situ; mIDC microinvasive ductal carcinoma; IDC invasive ductal carcinoma; SVAB stereotactic vacuum-assisted biopsy; US-CNB US-guided core needle biopsy; HER2 human epidermal growth factor receptor 2